

# EssilorLuxottica

## EssilorLuxottica to release new research findings at ARVO, including five-year clinical findings of Essilor Stellest lenses

- **Dedicated booth with instruments and sponsored sessions on myopia**
- **New research findings on myopia and light management by R&D and experts**
- **New findings showing that Essilor Stellest lenses saved one- and three-quarter dioptres of myopia over five years <sup>\*1</sup>**

**Charenton-le-Pont, France (April 22, 2024)** – EssilorLuxottica is proud to take part in the 2024 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) in Seattle, USA, where it will present new findings from its studies on advancements in myopia management with Essilor Stellest lenses, and on light management, focusing on topics such as light exposure and photochromic lenses. The full agenda can be viewed in the ARVO pocket guide [here](#).

EssilorLuxottica R&D experts will once again be present to showcase their work among their peers. In addition to joining poster presentations and sponsored sessions, attendees will have the opportunity to stop by booth #4815 where they can meet the Group's experts, see what is new at research and development and discover how EssilorLuxottica is shaping the future of vision care through transformative technologies.

The Company will also present the results of a five-year clinical follow-up study of its Essilor Stellest lenses for the first time. The findings strengthen the existing evidence base of the lenses in slowing down myopia progression in children. The data showed that the lenses save one- and three-quarter dioptres of myopia over five years,<sup>\*1</sup> demonstrating conclusive evidence of their efficacy in slowing down myopia progression in children in the fifth year.

The five-year results will be presented at an EssilorLuxottica sponsored session titled '*Novel approaches and models in myopia management: spectacle lenses with highly aspherical lenslets*', on May 5 at 11:00 local time. Dr. Björn Drobe from EssilorLuxottica's R&D team will present the results, along with Prof. Mark Bullimore, MCOptom, PhD, FAAO who will present his insights on predictive models for axial elongation and change in myopia progression.

On May 6 at 10:00 local time, Dr. Yee Ling Wong from EssilorLuxottica's R&D team and Prof. Mark Bullimore will discuss emmetropic eye growth and spectacle lenses with highly aspherical lenslets (HAL) based on findings from a recently published paper. This will be presented at a second sponsored myopia session titled '*Emmetropic eye growth as benchmark for myopia management using spectacle lenses with highly aspherical lenslets*'. Essilor Stellest lenses are based on the optical design of HAL lenses. Both sessions will be moderated by Olga Prenat, Head of Medical and Professional Affairs at EssilorLuxottica.

Norbert Gorny, Chief Scientific Officer at EssilorLuxottica, said, “We are excited to be able to share the latest five-year findings of HAL lenses at ARVO as long-term clinical data is essential to showcase the continued efficacy and performance of the lens in children. As we already know that every dioptre matters, we look forward to sharing scientific data and insights on interventions to address myopia, to bring us all one step closer to protecting the vision of young patients. We will also continue to integrate scientific knowledge with innovative technologies to create the future of myopia control spectacle lenses so that the next generation can see more and be more.”

“We are very happy to welcome attendees at our EssilorLuxottica booth where they can discover the company’s innovative R&D capabilities and expertise in vision care and meet our R&D and Medical and Professional Affairs teams. The booth will also feature our Digital Infinite Refraction range consisting of Vision-R™ 800, Vision-S™ 700 and our specialized biometer, the Myopia Expert™ 700, designed to monitor myopia progression based on refraction and axial length for effective myopia management,” said Olga Prenat, Head of Medical and Professional Affairs at EssilorLuxottica.

## Notes

\*Compared to the 60-month progression of the Virtual Control Group (predicted average annual decrease in SER by 9.7%, Smotherman C, et al. IOVS 2023;64:ARVO E-Abstract 811).

1 Li X, Huang Y, Liu C, Yin Z, Cui Z, Lim EW, Drobe B, Chen H, Bao J. Myopia control efficacy of Spectacle Lenses with Highly Aspherical Lenslets: results of a 5-year follow-up study. ARVO Annual Meeting, Seattle. 2024. Available at:

<https://epro02.ativ.me/web/page.php?nav=false&page=IntHtml&project=ARVO24&id=4045389&external=true> Last accessed 17 April 2024

## Contacts

**Olga Prenat**  
Head of Medical &  
Professional Affairs  
prenato@essilor.fr

**Marco Catalani**  
Head of Corporate Communications  
[media@essilorluxottica.com](mailto:media@essilorluxottica.com)

## About EssilorLuxottica

EssilorLuxottica is a global leader in the design, manufacture and distribution of ophthalmic lenses, frames and sunglasses. With over 200,000 employees across 150 countries, 650 operations facilities and 18,000 stores, in 2023 the Company generated consolidated revenue of Euro 25.4 billion. Its mission is to help people around the world to see more and be more by addressing their evolving vision needs and personal style aspirations. EssilorLuxottica is home to the most advanced lens technologies including Varilux, Stellest and Transitions, the most iconic eyewear brands including Ray-Ban and Oakley, the most desired luxury licensed brands and world-class retailers including LensCrafters and Sunglass Hut. The Company’s OneSight EssilorLuxottica Foundation has given access to sustainable vision care to more than 760 million people in underserved communities. The EssilorLuxottica share trades on the Euronext Paris market and is included in the Euro Stoxx 50 and CAC 40 indices. Codes and symbols: ISIN: FR0000121667; Reuters: ESLX.PA; Bloomberg: EL:FP [www.essilorluxottica.com](http://www.essilorluxottica.com)